Taxotere , Epirubicin — Competitive Intelligence Brief

Taxotere , Epirubicin (Taxotere , Epirubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 3 Taxane Microtubules Oncology Small molecule

Target snapshot

Taxotere , Epirubicin (Taxotere , Epirubicin) — National Taiwan University Hospital. Taxotere works by inhibiting microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the G2/M phase, and ultimately inducing apoptosis in cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Taxotere , Epirubicin TARGET	Taxotere , Epirubicin	National Taiwan University Hospital	phase 3	Taxane	Microtubules
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
Ivermectin + colchicine	Ivermectin + colchicine	Ain Shams University	marketed	Antiparasitic + anti-inflammatory combination	Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine)
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	Queensland Centre for Gynaecological Cancer	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

1. Sanofi · 3 drugs in this class
2. Akeso · 1 drug in this class
3. Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
4. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
5. Central European Society for Anticancer Drug Research · 1 drug in this class
6. Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
7. Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
8. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
9. Jina Pharmaceuticals Inc. · 1 drug in this class
10. Air Force Military Medical University, China · 1 drug in this class